Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …

Currently, limited information is available to clinicians regarding the long-term efficacy of
omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically …

Objective. Several clinical studies have demonstrated the effectiveness of omalizumab in
patients with severe allergic asthma but the treatment period has always been relatively …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Background and objective: The efficacy and safety of the anti‐IgE antibody, omalizumab,
has been widely studied in patients with asthma. However to date, no large studies have …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …